MA48862A - Méthode de traitement de tumeur immunothérapeutique - Google Patents

Méthode de traitement de tumeur immunothérapeutique

Info

Publication number
MA48862A
MA48862A MA048862A MA48862A MA48862A MA 48862 A MA48862 A MA 48862A MA 048862 A MA048862 A MA 048862A MA 48862 A MA48862 A MA 48862A MA 48862 A MA48862 A MA 48862A
Authority
MA
Morocco
Prior art keywords
treatment method
tumor treatment
immunotherapeutic
immunotherapeutic tumor
tumor
Prior art date
Application number
MA048862A
Other languages
English (en)
Inventor
Neel K Anand
Haiying Cai
Bo-Liang Deng
Marlene Hennessy
Bhalchandra V Joshi
Saul Kivimae
Zhongxu Ren
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA48862A publication Critical patent/MA48862A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA048862A 2017-05-02 2018-05-02 Méthode de traitement de tumeur immunothérapeutique MA48862A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500486P 2017-05-02 2017-05-02
US201762502051P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
MA48862A true MA48862A (fr) 2020-04-01

Family

ID=64016803

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048862A MA48862A (fr) 2017-05-02 2018-05-02 Méthode de traitement de tumeur immunothérapeutique

Country Status (11)

Country Link
US (1) US12054553B2 (fr)
EP (1) EP3628010A4 (fr)
JP (1) JP7165680B2 (fr)
KR (1) KR102785429B1 (fr)
CN (1) CN110582300B (fr)
AU (1) AU2018261102B2 (fr)
CA (1) CA3062291A1 (fr)
IL (1) IL270329B2 (fr)
MA (1) MA48862A (fr)
MX (1) MX2019013071A (fr)
WO (1) WO2018204528A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628010A4 (fr) 2017-05-02 2021-02-17 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222296A1 (fr) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 12 activables et procédés d'utilisation associés
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
SG11202105835YA (en) * 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
CA3136066A1 (fr) * 2019-04-05 2020-10-08 Sumitomo Dainippon Pharma Co., Ltd. Adjuvant hydrosoluble, et composition comprenant celui-ci
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
US20220370563A1 (en) * 2019-10-25 2022-11-24 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE10248141B4 (de) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US20050079155A1 (en) 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2611823C (fr) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugues a liaison degradable et reactifs polymeres utilises dans la preparation de ces conjugues
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
CA2798616A1 (fr) 2010-05-07 2011-11-10 Baylor Research Institute Amorcage croise medie par des immunorecepteurs de cellules dendritiques (dcir) de lymphocytes t cd8+ humains
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US20130331443A1 (en) * 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
EP2672993A1 (fr) * 2011-02-10 2013-12-18 University of Louisville Research Foundation, Inc. Compositions d'adjuvant avec 4-1bbl
PT3134123T (pt) * 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
AU2018207283C1 (en) 2017-01-10 2024-05-02 Nektar Therapeutics Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
EP3628010A4 (fr) 2017-05-02 2021-02-17 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique
US12030940B2 (en) * 2017-08-17 2024-07-09 Nektar Therapeutics Immunotherapeutic tumor treatment method

Also Published As

Publication number Publication date
IL270329A (fr) 2019-12-31
WO2018204528A1 (fr) 2018-11-08
KR20190141760A (ko) 2019-12-24
EP3628010A4 (fr) 2021-02-17
IL270329B2 (en) 2025-12-01
AU2018261102B2 (en) 2025-01-23
CA3062291A1 (fr) 2018-11-08
JP2020518610A (ja) 2020-06-25
US12054553B2 (en) 2024-08-06
EP3628010A1 (fr) 2020-04-01
KR102785429B1 (ko) 2025-03-21
MX2019013071A (es) 2019-12-11
AU2018261102A1 (en) 2019-11-07
CN110582300B (zh) 2024-08-02
JP7165680B2 (ja) 2022-11-04
IL270329B1 (en) 2025-08-01
CN110582300A (zh) 2019-12-17
US20210292425A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL269026A (en) Methods of treating tumor
EP3628010A4 (fr) Méthode de traitement de tumeur immunothérapeutique
PL3288581T3 (pl) Sposób leczenia nowotworu
EP3820461A4 (fr) Méthode de traitement du cancer
IL269371A (en) Treatment methods
IL255261A0 (en) Methods for treating cancer
MA43374A (fr) Méthodes de traitement de tumeurs malignes
EP3341080A4 (fr) Méthode de traitement du cancer
HUE038541T2 (hu) Rák kezelési módszerek
MA47408A (fr) Traitement du cancer
HUE049511T2 (hu) Módszer magok stimulálására
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3389634A4 (fr) Méthodes de traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
PT3265087T (pt) Método de tratamento com tradipitant
EP3375440A4 (fr) Méthode de traitement de la mucosite
EP3448365A4 (fr) Méthode de traitement de la constipation
IL257764B (en) Methods for treatment of diseases
PL3393468T3 (pl) Metody leczenia niedoboru odporności
EP3389652A4 (fr) Méthodes de traitement du cancer
IL281600A (en) Methods of treating cancer
SI3532076T1 (sl) Imunoterapevtska zdravljenja tumorjev
EP3733175A4 (fr) Traitement du cancer